Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.
Multibranched peptides (SPCs) derived either from the fusion protein (gp41) sequence or from the cleavage sequence of the human immunodeficiency virus type 1 envelope were chemically synthesized and tested for their ability to inhibit both syncytium formation and HIV production in CD4+ cells. The gp41-derived SPCs had no effect. In contrast, an SPC encompassing the envelope cleavage sites strongly inhibited both HIV Env-induced syncytium formation and viral production.
Sabatier
J M
JM
CNRS URA 1455, Institut Fédératif de Recherche Jean Roche, Faculté de Médecine Nord, Marseille, France.
Mabrouk
K
K
Moulard
M
M
Rochat
H
H
Van Rietschoten
J
J
Fenouillet
E
E
D000595:Amino Acid Sequence; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology; D002478:Cells, Cultured; D015726:Giant Cells / Q000187:drug effects / Q000821:virology; D015699:HIV Envelope Protein gp120 / Q000235:genetics* / Q000494:pharmacology*; D015700:HIV Envelope Protein gp41 / Q000235:genetics* / Q000494:pharmacology*; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000235:genetics*; D008969:Molecular Sequence Data; D011994:Recombinant Proteins / Q000138:chemical synthesis / Q000494:pharmacology
D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D011994:Recombinant Proteins